Results 61 to 70 of about 4,521 (193)

Filgotinib Effectiveness in Rheumatoid Arthritis: Observational Analysis of a Large Multicenter Cohort. [PDF]

Rheumatol Ther
The efficacy and safety of filgotinib (FIL) for the treatment of patients with rheumatoid arthritis (RA) have been evaluated in a number of randomized controlled trials.
Celletti E, Di Penta M, Ariani A, Parisi S, Andracco R, Raffeiner B, Ianniello A, Lo Gullo A, Molica Colella AB, Priora M, Paroli M, Lumetti F, Ravagnani V, Girelli F, Vitetta R, Volpe A, Scolieri P, Bezzi A, Ometto F, Visalli E, Farina A, Del Medico P, Bravi E, Colina M, Larosa M, Serale F, Franchina V, Molica Colella F, Ferrero G, Sandri G, Addimanda O, Reta M, Mascella F, Focherini MC, Fiorenza A, Rovera G, Giampietro C, Bernardi S, Mansueto N, Camellino D, Caccavale R, Nucera V, Sabatini E, Del Biondo P, Ditto MC, Platè I, Adorni G, Di Donato E, Santilli D, Lucchini G, Amato G, De Lucia F, Dal Bosco Y, Foti R, Smerilli G, Bianchi G, Foti R, Arrigoni E, Marchetta A, Bixio R, Bruzzese V, Fusaro E, Giuggioli D, Salvarani C, Cipollone F, Becciolini A.   +65 more
europepmc   +2 more sources

JAK Inhibitors and Memory Impairment: Disproportionality Analyses in the WHO Global Pharmacovigilance Database, VigiBase

Fundamental &Clinical Pharmacology, Volume 40, Issue 1, January 2026.
ABSTRACT Background Chronic inflammation is involved in various mechanisms of memory impairment (MI). Although Janus kinase inhibitors (JAKi), which inhibit cytokine‐induced JAK–STAT pathway, could theoretically protect against MI, we faced an unexpected case of MI in a non‐elderly patient treated with JAKi.
Marilou Duboëlle, Adriano Lercara, Yves‐Marie Pers, Céline Michel, Marion Lepelley, Marie‐Blanche Valnet‐Rabier, Jean‐Luc Faillie, Virginie Bres, Pascale Palassin   +8 more
wiley   +1 more source

Role of Janus kinase Inhibitors (JAKis) in Autoimmune Disorders: Review [PDF]

JAK inhibitors (JAKis) comprise a crucial therapeutic tool for managing patients with immune-mediated inflammatory disorders. Although often perceived as a uniform class of medications thought to be largely interchangeable, notable variances exist in ...
H. Shehata, Lamia, M. Nasr, Mohamed, Naser, Maged   +2 more
core   +2 more sources

Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study [PDF]

, 2016
Objectives: To evaluate the efficacy and safety of different doses and regimens of filgotinib, an oral JAK1 inhibitor, as add-on treatment to methotrexate (MTX) in patients with active rheumatoid arthritis (RA) and inadequate response to MTX. Methods: In
Alten, R, Enriquez-Sosa, F, Greenwald, M, Harrison, P, Mazur, M, Pavlova, D, Tasset, C, Taylor, Peter, Van der Aa, A, Vanhoutte, F, Westhovens, R   +10 more
core   +2 more sources

A Phase Ib Investigator-Initiated Trial of Filgotinib in Patients With Idiopathic Multicentric Castleman Disease

Cureus
Background Idiopathic multicentric Castleman disease (iMCD) is a chronic systemic inflammatory disease characterized by the production of interleukin (IL)-6.
S. Fukui, R. Sumiyoshi, T. Koga, N. Hosogaya, Sawana Narita, S. Morimoto, Hiroshi Yano, Atsushi Katsube, S. Yano, Y. Masaki, Shinichiro Tsunoda, S. Sato, Kiyoshi Migita, Kazuko Matsuyama, Naoki Kato, Atsuhiko Kawamoto, A. Kawakami   +16 more
semanticscholar   +1 more source

Musculoskeletal Diseases: Mechanisms and Therapeutic Advances

MedComm, Volume 6, Issue 12, December 2025.
Musculoskeletal diseases comprise a broad spectrum of inflammatory, degenerative, and neoplastic disorders. Increasing evidence highlights the central role of immune regulation in their pathogenesis, with complex interactions among immune, bone, muscle, and stromal cells.
Xiao Ma, Eloy Yinwang, Xupeng Chai, Fangqian Wang, Zehao Chen, Shengdong Wang, Hao Zhou, Yucheng Xue, Jiangchu Lei, Fanglu Chen, Hengyuan Li, Shixin Chen, Shenzhi Zhao, Kelei Wang, Liang Chen, Junjie Gao, Zhaoming Ye, Nong Lin   +17 more
wiley   +1 more source

Protocol: Filgotinib in addition to methotrexate versus filgotinib monotherapy in patients with rheumatoid arthritis with an inadequate response to methotrexate: A multicenter, prospective, open-label, randomized controlled trial (FAITHFUL Study). [PDF]

PLoS One
Background Filgotinib (FIL), a Janus kinase-1 preferential inhibitor, has been studied for its efficacy and safety in rheumatoid arthritis. The FINCH3 trial compared FIL monotherapy, FIL plus methotrexate (MTX) combination therapy, and MTX monotherapy in
Akiyama M, Hidaka T, Kaneko M, Ito S, Taguchi H, Ishii T, Asai S, Hirata S, Ikeda K, Suzuki K, Kato N, Kaneko Y.   +11 more
europepmc   +2 more sources

The extending scope of kinase inhibition in immune diseases [PDF]

, 2018
No abstract ...
McInnes, Iain B., Siebert, Stefan
core   +1 more source

International Survey of Gastroenterologists on Managing Inflammatory Bowel Disease During Pregnancy and Lactation: Current State and the Necessity for Improvements

United European Gastroenterology Journal, Volume 13, Issue 10, Page 1999-2011, December 2025.
ABSTRACT Background Reproduction is a fundamental aspect of life. This study aimed to provide an international overview of gastroenterologists' approaches to managing inflammatory bowel disease (IBD) during preconception, pregnancy, lactation, and postpartum. Methods An anonymous 75‐question survey was distributed to gastroenterologists in 36 countries,
María José Casanova, Javier P. Gisbert, Aurelien Amiot, Hannah Gordon, Gionata Fiorino, Emma Flanagan, Paulo Gustavo Kotze, Aleksandra Sokic‐Milutinovic, Elena Sonnenberg, Paulina Nuñez, Andreas Blesl, Ignacio Catalán‐Serra, Peter Bossuyt, Rafal Filip, Ariella Bar‐Gil Shitrit, Anna Kagramanova, Zeljko Krznaric, Paulina Molander, Gerassimos J. Mantzaris, Pascal Juillerat, Tamas Molnar, Krisztina B. Gecse, Joana Torres, Pär Myrelid, Uma Mahadevan, Juan Ricardo Márquez, Beatriz Maria Iade‐Vergara, Astrid Rausch, Dana Duricova, Mette Julsgaard, María Chaparro   +30 more
wiley   +1 more source

Simultaneous Quantification of Filgotinib and Its Active Metabolite in Human Plasma Using Liquid Chromatography-Tandem Mass Spectrometry: Validation and Clinical Application. [PDF]

Biomed Chromatogr
Filgotinib (FLG) is a Janus kinase 1 inhibitor and is metabolized to an active metabolite, GS‐829845. There is no report on the method for simultaneous quantification of FLG and GS‐829845 in clinical samples.
Ito T, Suno M, Shintani M, Iwata A, Fujii T, Matsubara K.   +5 more
europepmc   +2 more sources